Fresenius Kabi announced the launch of Micafungin for Injection, a generic version of Mycamine (micafungin for injection; Astellas Pharma).
Micafungin, a member of the echinocandin class of antifungal agents, is indicated for the treatment of:
- Candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses in adult and pediatric patients aged ≥4 months.
- Candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients aged <4 months.
- Esophageal candidiasis in adult and pediatric patients aged ≥4 months.
- Prophylaxis of Candida infections in adult and pediatric patients aged ≥4 months undergoing hematopoietic stem cell transplantation (HSCT).
“We’re pleased to offer the first Micafungin generic in the United States, expanding our anti-infective portfolio, and increasing supply of this much-needed medication.” said John Ducker, president and CEO of Fresenius Kabi USA.
The product is available in 50mg and 100mg single-dose vials.
For more information visit fresenius-kabi.com.
This article originally appeared on MPR